Retatrutide (LY-3437943) is a synthetic triple-receptor agonist peptide that Durham Peptides supplies as research-grade 10 mg lyophilized vials, stocked and shipped domestically for researchers across Canada. It acts on three metabolic pathways at once — GLP-1, GIP, and glucagon — and is sometimes informally called "GLP-3" for this three-receptor mechanism.
Because it engages an additional glucagon pathway beyond dual-agonist compounds, retatrutide is frequently studied alongside Semaglutide (a mono-agonist) and Tirzepatide (a dual-agonist) to compare multi-receptor pharmacology. Durham Peptides stocks all three for comparative research.
BENEFITS
Triple receptor activation — studied for simultaneous GLP-1, GIP, and glucagon engagement
Metabolic research — explored in Phase 2 clinical trials with notable body-composition results
Glucagon component — linked to thermogenesis and energy-expenditure pathways
Next-generation compound — investigated as an advancement over dual-agonist approaches
Comparative pharmacology — assessed alongside mono- and dual-agonists in research settings
WHAT RESEARCHERS LOOK AT
Triple-agonist binding affinity across GLP-1, GIP, and glucagon receptors
Additive effects of glucagon-receptor activation on energy expenditure
Dose-response and tolerability profiling from clinical-trial data
Comparative outcomes vs tirzepatide and semaglutide
Pharmacokinetic profiling and receptor selectivity
